CRISPR Therapeutics AG (CRSP)
CRISPR Therapeutics AG (CRSP) is a biotechnology company focused on developing gene-editing therapies using CRISPR-Cas9 technology. Founded in 2013 and headquartered in Switzerland, the company aims to create transformative treatments for serious diseases by enabling precise genetic modifications. CRISPR Therapeutics collaborates with various partners to advance therapies for conditions such as blood disorders, cancer, and rare genetic diseases.
Company News
The global cell therapy market is projected to grow from $5.88 billion in 2024 to $44.39 billion by 2034, driven by rising demand for regenerative medicine, advancements in biotechnology, and increasing prevalence of chronic diseases.
CRISPR Therapeutics will present Phase 1 clinical data on its investigational gene editing therapy CTX310 targeting cardiovascular and cardiometabolic disease at the AHA Scientific Sessions in November 2025.
Despite challenges in 2023, Vertex Pharmaceuticals remains an attractive biotech stock with strong growth potential, particularly in cystic fibrosis treatments and new drug developments like Casgevy and Journavx.
CRISPR Therapeutics (CRSP) stock is trading near 5-year lows, but the company's gene editing treatment CASGEVY for sickle cell disease and beta-thalassemia has been approved in multiple jurisdictions. The company's future growth potential in gene editing is promising, but the high cost of CASGEVY may be a challenge.
Vertex Pharmaceuticals reported a wider-than-expected Q2 loss due to costs related to the acquisition of Alpine Immune Sciences. However, the company's strong fundamentals, including its dominant position in the cystic fibrosis market and a robust pipeline, make it a good long-term investment despite the recent stock price dip.
